Ionis Pharmaceuticals Inc. reported strong financial performance, with preliminary U.S. net product sales for TRYNGOLZA® (olezarsen) reaching $105 million in 2025, surpassing expectations as the first FDA-approved treatment for familial chylomicronemia syndrome (FCS). The company has raised its annual peak net sales guidance for TRYNGOLZA to over $2 billion for severe hypertriglyceridemia (sHTG). Ionis is poised for continued momentum in 2026, anticipating two additional independent product launches and several pivotal Phase 3 data readouts. The company expects accelerating revenue growth and aims to achieve cash flow breakeven in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.